Lenz Therapeutics, INC Schedule 13D activist filings

Versant Venture Capital funds have reported a material decrease in their aggregate beneficial ownership of LENZ Therapeutics, Inc. common stock, driven by share sales and dilution.

RA Capital Management and its affiliates report a dilution of their beneficial ownership in LENZ THERAPEUTICS, INC. to 13.6% of common stock outstanding.

Versant Venture Capital entities have significantly reduced their beneficial ownership in LENZ Therapeutics, Inc. through a series of stock sales in August and September 2025.

Versant Venture Capital funds have reduced their beneficial ownership in LENZ Therapeutics, Inc. through recent share sales totaling over $10 million.

Versant Venture Capital VI, L.P. has significantly reduced its beneficial ownership in LENZ Therapeutics, Inc. through two recent stock sales totaling over $12.5 million.

Versant Venture Capital VI, L.P. and Versant Venture Capital VII, L.P. have reported significant sales of LENZ Therapeutics, Inc. common stock, reducing their beneficial ownership.

Versant Venture Capital and its affiliated funds have filed an Amendment No. 4 to their Schedule 13D, reporting a reduction in their beneficial ownership of LENZ Therapeutics, Inc. common stock following a significant share sale.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13D, confirming their beneficial ownership of 15.1% of LENZ Therapeutics, Inc.'s common stock.